Congenica chosen to provide clinical decision software to NHS Genomic Medicine Service

Image of London Parliament
NHS’ Genomic Medicine Service began mobilizing earlier this month, with a network that will include laboratory hubs spread out across the country. (Avanti)

Congenica has been tapped by Genomics England to provide clinical decision support services for the NHS Genomic Medicine Service, which aims to make genetic testing a routine element of delivering healthcare.

The multiyear contract will employ Congenica’s Sapientia genome interpretation software platform.

“By working with Congenica from the start of the 100,000 Genomes Project, we’ve been able to provide high quality variant interpretation of genome sequences to the NHS, helping deliver benefits to patients at scale,” Genomics England Chief Executive John Mattick said in a statement.


How ICON, Lotus, and Bioforum are Improving Study Efficiency with a Modern EDC

CROs are often at the forefront of adopting new technologies to make clinical trials more efficient. Hear how ICON, Lotus Clinical Research, and Bioforum are speeding database builds and automating reporting tasks for data management.

NHS’ genomic service began mobilizing earlier this month, with a network that will include genomic laboratory hubs spread out across the country. Initially, patients with cancer and rare and inherited diseases will be able to access genomic testing, before it opens to other populations.

“Genomics England and the NHS have done extraordinary work in building the foundations for the Genomic Medicine Service,” said Congenica CEO David Atkins, Ph.D., describing the initiative as the world’s first of its kind.

RELATED: IQVIA and Genomics England to launch real-world research platform as the U.K. looks to boost cancer diagnostics

Sapientia was validated on approximately 10,000 genomes during Genomics England’s 100,000 Genomes Project, with Congenica scientists using the platform to analyze patients’ genetic code and produce actionable clinical reports.

The 100,000 Genomes Project is expected to reach its goal before the end of 2018; as of Oct. 1, the program has sequenced 87,231 whole genomes.

Suggested Articles

FDA staff took the action in response to cases of early growth plate closure in children on the retinoic acid receptor gamma agonist.

The CTAD presentation cleared up some questions about the data set without delivering a telling blow for either side of the debate.

The FDA has shot down Enzyvant's RVT-802, a rare immunodeficiency disease candidate, citing manufacturing concerns.